Canadian Manufacturing

MediPharm Labs appoints new CFO

Greg Hunter was previously CFO of Medical Pharmacies Group Limited, a medical equipment manufacturer and distributor in Canada.

January 29, 2021  by CM Staff

TORONTO — MediPharm Labs Corp., a cannabis extraction, distillation and derivative products company, announces that Greg Hunter will join MediPharm Labs as Chief Financial Officer (CFO), effective February 8, 2021.

Greg Hunter brings over 20 years of experience as a business executive holding various senior finance and leadership roles across multiple industries including healthcare distribution, telecommunications, pharmaceuticals, biotechnology, medical device and consumer packaged goods. Greg also brings a background in capital management, audit, compliance, tax, treasury, ERP, manufacturing, contract management and pricing strategy.

“As MediPharm continues to focus on accelerating the growth and execution of our global pharmaceutical, health and wellness business, Greg’s background in growing large pharmaceutical operations combined with a track record in strategic capital allocation and cost management is a strong addition to our Company,” said Keith Strachan, President and Interim CEO, MediPharm Labs. “As we look to seize new growth opportunities and expand our product offerings, his addition will ensure that we are well positioned to execute on our plans and deliver profitable growth in the future.”

Most recently, Greg was Chief Financial Officer of Medical Pharmacies Group Limited, a medical equipment manufacturer and distributor in Canada. Greg holds an MBA from McMaster University, an Honors B.Sc. in Microbiology and Immunology from University of Western Ontario and is a Chartered Professional Accountant.

Advertisment

In connection with Greg’s appointment as CFO, the Company granted 600,000 stock options to him with an exercise price set at the close of business on January 28, 2021. Each grant has a five-year term expiring January 28, 2026, and vests in five equal instalments, the first of which vests immediately with the four other instalments vesting on the dates which are six, twelve, eighteen and twenty-four months from the grant date. The stock options are subject to any necessary regulatory approvals.


Print this page

Related Stories